Literature DB >> 20702625

Soluble HLA-G inhibits myeloid dendritic cell function in HIV-1 infection by interacting with leukocyte immunoglobulin-like receptor B2.

Jinghe Huang1, Patrick Burke, Yue Yang, Katherine Seiss, Jill Beamon, Thai Cung, Ildiko Toth, Florencia Pereyra, Mathias Lichterfeld, Xu G Yu.   

Abstract

Dendritic cells represent a specialized class of professional antigen-presenting cells that are responsible for priming and maintaining antigen-specific effector cell responses and regulating immune activation by cytokine secretion. In HIV-1 infection, myeloid dendritic cells are highly dysfunctional, but mechanisms contributing to their functional alterations are not well defined. Here, we show that soluble molecules of the nonclassical major histocompatibility complex class Ib (MHC-Ib) antigen HLA-G are highly upregulated in the plasma during progressive HIV-1 infection, while levels of membrane-bound HLA-G surface expression on dendritic cells, monocytes, and T cells only slightly differ among HIV-1 progressors, HIV-1 elite controllers, and HIV-1-negative persons. These elevated levels of soluble HLA-G in progressive HIV-1 infection likely result from increased secretion of intracellularly stored HLA-G molecules in monocytes and dendritic cells and contribute to a functional disarray of dendritic cells by inhibiting their antigen-presenting properties, while simultaneously enhancing their secretion of proinflammatory cytokines. Interestingly, we observed that these immunoregulatory effects of soluble HLA-G were mainly mediated by interactions with the myelomonocytic HLA class I receptor leukocyte immunoglobulin-like receptor B2 (LILRB2; ILT4), while binding of soluble HLA-G to its alternative high-affinity receptor, LILRB1 (ILT2), appeared to be less relevant for its immunomodulatory functions on dendritic cells. Overall, these results demonstrate a critical role for soluble HLA-G in modulating the functional characteristics of professional antigen-presenting cells in progressive HIV-1 infection and suggest that soluble HLA-G might represent a possible target for immunotherapeutic interventions in HIV-1-infected persons.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20702625      PMCID: PMC2950595          DOI: 10.1128/JVI.01292-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

Review 1.  Immunobiology of dendritic cells.

Authors:  J Banchereau; F Briere; C Caux; J Davoust; S Lebecque; Y J Liu; B Pulendran; K Palucka
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load.

Authors:  H Donaghy; A Pozniak; B Gazzard; N Qazi; J Gilmour; F Gotch; S Patterson
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

3.  Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules.

Authors:  Catherine Menier; Berta Saez; Vaclav Horejsi; Silvia Martinozzi; Irene Krawice-Radanne; Sylvie Bruel; Caroline Le Danff; Murielle Reboul; Ivan Hilgert; Michèle Rabreau; Mur Luis Larrad; Marika Pla; Edgardo D Carosella; Nathalie Rouas-Freiss
Journal:  Hum Immunol       Date:  2003-03       Impact factor: 2.850

4.  Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule.

Authors:  José M Lozano; Rafael González; José M Kindelán; Nathalie Rouas-Freiss; Rafael Caballos; Jean Dausset; Edgardo D Carosella; José Peña
Journal:  AIDS       Date:  2002-02-15       Impact factor: 4.177

5.  CD8(+)HLA-G(+) regulatory T cells are expanded in HIV-1-infected patients.

Authors:  Jose Manuel Lozano; Rafael González; Juan Luque; Mario Frias; Antonio Rivero; Jose Peña
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

6.  Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1.

Authors:  Heather Donaghy; Brian Gazzard; Frances Gotch; Steven Patterson
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

7.  Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection.

Authors:  Johan K Sandberg; Noam M Fast; Emil H Palacios; Glenn Fennelly; Joanna Dobroszycki; Paul Palumbo; Andrew Wiznia; Robert M Grant; Nina Bhardwaj; Michael G Rosenberg; Douglas F Nixon
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56 bright subset.

Authors:  Paola Mantegani; Giuseppe Tambussi; Laura Galli; Chiara Tassan Din; Adriano Lazzarin; Claudio Fortis
Journal:  Immunology       Date:  2009-08-04       Impact factor: 7.397

Review 9.  The interaction of immunodeficiency viruses with dendritic cells.

Authors:  R M Steinman; A Granelli-Piperno; M Pope; C Trumpfheller; R Ignatius; G Arrode; P Racz; K Tenner-Racz
Journal:  Curr Top Microbiol Immunol       Date:  2003       Impact factor: 4.291

10.  Tissue-specific B-cell dysfunction and generalized memory B-cell loss during acute SIV infection.

Authors:  Sandrine Peruchon; Nada Chaoul; Chantal Burelout; Benoit Delache; Patricia Brochard; Pascale Laurent; Fabrice Cognasse; Sophie Prévot; Olivier Garraud; Roger Le Grand; Yolande Richard
Journal:  PLoS One       Date:  2009-06-19       Impact factor: 3.240

View more
  21 in total

1.  Non-classical MHC-Ι genes in chronic hepatitis B and hepatocellular carcinoma.

Authors:  Jian Zhang; Lelin Pan; Luyan Chen; Xiaowen Feng; Lin Zhou; Shusen Zheng
Journal:  Immunogenetics       Date:  2011-10-21       Impact factor: 2.846

Review 2.  The emerging role of leukocyte immunoglobulin-like receptors (LILRs) in HIV-1 infection.

Authors:  Mathias Lichterfeld; Xu G Yu
Journal:  J Leukoc Biol       Date:  2011-10-25       Impact factor: 4.962

Review 3.  New Targets for Antiviral Therapy: Inhibitory Receptors and Immune Checkpoints on Myeloid Cells.

Authors:  Yanni Liu; Paul Nicklin; Yuan He
Journal:  Viruses       Date:  2022-05-25       Impact factor: 5.818

4.  KIR2DL4 (CD158d): An activation receptor for HLA-G.

Authors:  Sumati Rajagopalan; Eric O Long
Journal:  Front Immunol       Date:  2012-08-20       Impact factor: 7.561

5.  High level of soluble HLA-G in the female genital tract of Beninese commercial sex workers is associated with HIV-1 infection.

Authors:  Valérie Thibodeau; Julie Lajoie; Annie-Claude Labbé; Marcel D Zannou; Keith R Fowke; Michel Alary; Johanne Poudrier; Michel Roger
Journal:  PLoS One       Date:  2011-09-23       Impact factor: 3.240

6.  Tolerogenic function of dimeric forms of HLA-G recombinant proteins: a comparative study in vivo.

Authors:  Benoit Favier; Kiave-Yune HoWangYin; Juan Wu; Julien Caumartin; Marina Daouya; Anatolij Horuzsko; Edgardo D Carosella; Joel LeMaoult
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

7.  Systemic inhibition of myeloid dendritic cells by circulating HLA class I molecules in HIV-1 infection.

Authors:  Jinghe Huang; Maha Al-Mozaini; Jerome Rogich; Mary F Carrington; Katherine Seiss; Florencia Pereyra; Mathias Lichterfeld; Xu G Yu
Journal:  Retrovirology       Date:  2012-01-30       Impact factor: 4.602

8.  Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10.

Authors:  Jie Liu; Linlin Wang; Wei Gao; Liwen Li; Xia Cui; Hongyan Yang; Wenli Lin; Qi Dang; Nan Zhang; Yuping Sun
Journal:  Diagn Pathol       Date:  2014-04-24       Impact factor: 2.644

9.  Functional characterization of HLA-G⁺ regulatory T cells in HIV-1 infection.

Authors:  Chun Li; Ilona Toth; Julian Schulze Zur Wiesch; Florencia Pereyra; Jennifer Rychert; Eric S Rosenberg; Jan van Lunzen; Mathias Lichterfeld; Xu G Yu
Journal:  PLoS Pathog       Date:  2013-01-31       Impact factor: 6.823

Review 10.  Immunomodulatory properties of HLA-G in infectious diseases.

Authors:  Laurence Amiot; Nicolas Vu; Michel Samson
Journal:  J Immunol Res       Date:  2014-04-15       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.